HIGHLIGHTS
- who: Anusha Muralidhar and colleagues from the University of Wisconsin Carbone Cancer Center, Highland Madison, WI, USA have published the research work: Targeted Radiation and Immune Therapiesu2014Advances and Opportunities for the Treatment of Prostate Cancer, in the Journal: Pharmaceutics 2023, 15, 252. of /2023/
- what: This trial demonstrated that Lu-PSMA therapy was effective in generating a longer radiological progression-free survival (rPFS, 8.7 months) in patients with PSMA+ mCRPC who previously received standard of care therapies, as well as overall survival (15.3 months), compared to 3.4 and 11.3 months, respectively . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.